What is the projected market valuation of the Infection Surveillance Solution Market by 2035?

The projected market valuation for the Infection Surveillance Solution Market by 2035 is 2.158 USD Billion. Read More

What was the market valuation of the Infection Surveillance Solution Market in 2024?

The overall market valuation of the Infection Surveillance Solution Market was 0.8 USD Billion in 2024. Read More

What is the expected CAGR for the Infection Surveillance Solution Market during the forecast period 2025 - 2035?

The expected CAGR for the Infection Surveillance Solution Market during the forecast period 2025 - 2035 is 9.44%. Read More

Which companies are considered key players in the Infection Surveillance Solution Market?

Key players in the Infection Surveillance Solution Market include Cerner Corporation, McKesson Corporation, Epic Systems Corporation, and IBM Watson Health. Read More

What are the main deployment segments in the Infection Surveillance Solution Market?

The main deployment segments in the Infection Surveillance Solution Market are Cloud-based and On-premises, each valued at 1.079 USD Billion by 2035. Read More

What applications are driving growth in the Infection Surveillance Solution Market?

Applications driving growth include Healthcare-associated infections, Antimicrobial resistance surveillance, and Vaccine effectiveness monitoring. Read More

What types of infections are monitored within the Infection Surveillance Solution Market?

The types of infections monitored include Bacterial infections, Viral infections, and Fungal infections, with Bacterial infections projected to reach 0.85 USD Billion by 2035. Read More

How do electronic health records contribute to the Infection Surveillance Solution Market?

Electronic health records (EHRs) are a significant data source, projected to reach 0.84 USD Billion by 2035. Read More

What is the significance of patient portals in the Infection Surveillance Solution Market?

Patient portals are expected to contribute 0.67 USD Billion to the Infection Surveillance Solution Market by 2035. Read More

How does the market for antimicrobial resistance surveillance appear to be evolving?

The market for antimicrobial resistance surveillance is projected to grow to 0.63 USD Billion by 2035, indicating a rising focus on this critical area. Read More

Infection Surveillance Solution Market

ID: MRFR/HC/24563-HCR

128 Pages

Satyendra Maurya

Last Updated: April 06, 2026

Infection Surveillance Solution Market Size, Growth Research Report By Deployment (Cloud-based, On-premises), By Application (Healthcare-associated infections (HAIs), Antimicrobial resistance surveillance, Vaccine effectiveness monitoring), By Data Source (Electronic health records (EHRs), Laboratory information systems (LISs), Patient portals), By Type of Infection (Bacterial infections, Viral infections, Fungal infections) - Competitor Industry Analysis and Trends Forecast Till 2035

Infection Surveillance Solution Market Infographic

Summary Table of Contents Segmentation Download PDF

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Healthcare, BY Deployment (USD Billion)
  1. 4.1.1 Cloud-based
  2. 4.1.2 On-premises
2. 4.2 Healthcare, BY Application (USD Billion)
  1. 4.2.1 Healthcare-associated infections (HAIs)
  2. 4.2.2 Antimicrobial resistance surveillance
  3. 4.2.3 Vaccine effectiveness monitoring
3. 4.3 Healthcare, BY Data Source (USD Billion)
  1. 4.3.1 Electronic health records (EHRs)
  2. 4.3.2 Laboratory information systems (LISs)
  3. 4.3.3 Patient portals
4. 4.4 Healthcare, BY Type of Infection (USD Billion)
  1. 4.4.1 Bacterial infections
  2. 4.4.2 Viral infections
  3. 4.4.3 Fungal infections
5. 4.5 Healthcare, BY Region (USD Billion)
  1. 4.5.1 North America
    1. 4.5.1.1 US
    2. 4.5.1.2 Canada
  2. 4.5.2 Europe
    1. 4.5.2.1 Germany
    2. 4.5.2.2 UK
    3. 4.5.2.3 France
    4. 4.5.2.4 Russia
    5. 4.5.2.5 Italy
    6. 4.5.2.6 Spain
    7. 4.5.2.7 Rest of Europe
  3. 4.5.3 APAC
    1. 4.5.3.1 China
    2. 4.5.3.2 India
    3. 4.5.3.3 Japan
    4. 4.5.3.4 South Korea
    5. 4.5.3.5 Malaysia
    6. 4.5.3.6 Thailand
    7. 4.5.3.7 Indonesia
    8. 4.5.3.8 Rest of APAC
  4. 4.5.4 South America
    1. 4.5.4.1 Brazil
    2. 4.5.4.2 Mexico
    3. 4.5.4.3 Argentina
    4. 4.5.4.4 Rest of South America
  5. 4.5.5 MEA
    1. 4.5.5.1 GCC Countries
    2. 4.5.5.2 South Africa
    3. 4.5.5.3 Rest of MEA
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Healthcare
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 Cerner Corporation (US)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 McKesson Corporation (US)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 Epic Systems Corporation (US)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 IBM Watson Health (US)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 Siemens Healthineers (DE)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 Philips Healthcare (NL)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 Medtronic (US)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 Oracle Corporation (US)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
  9. 5.2.9 Roche Diagnostics (CH)
    1. 5.2.9.1 Financial Overview
    2. 5.2.9.2 Products Offered
    3. 5.2.9.3 Key Developments
    4. 5.2.9.4 SWOT Analysis
    5. 5.2.9.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 NORTH AMERICA MARKET ANALYSIS
3. 6.3 US MARKET ANALYSIS BY DEPLOYMENT
4. 6.4 US MARKET ANALYSIS BY APPLICATION
5. 6.5 US MARKET ANALYSIS BY DATA SOURCE
6. 6.6 US MARKET ANALYSIS BY TYPE OF INFECTION
7. 6.7 CANADA MARKET ANALYSIS BY DEPLOYMENT
8. 6.8 CANADA MARKET ANALYSIS BY APPLICATION
9. 6.9 CANADA MARKET ANALYSIS BY DATA SOURCE
10. 6.10 CANADA MARKET ANALYSIS BY TYPE OF INFECTION
11. 6.11 EUROPE MARKET ANALYSIS
12. 6.12 GERMANY MARKET ANALYSIS BY DEPLOYMENT
13. 6.13 GERMANY MARKET ANALYSIS BY APPLICATION
14. 6.14 GERMANY MARKET ANALYSIS BY DATA SOURCE
15. 6.15 GERMANY MARKET ANALYSIS BY TYPE OF INFECTION
16. 6.16 UK MARKET ANALYSIS BY DEPLOYMENT
17. 6.17 UK MARKET ANALYSIS BY APPLICATION
18. 6.18 UK MARKET ANALYSIS BY DATA SOURCE
19. 6.19 UK MARKET ANALYSIS BY TYPE OF INFECTION
20. 6.20 FRANCE MARKET ANALYSIS BY DEPLOYMENT
21. 6.21 FRANCE MARKET ANALYSIS BY APPLICATION
22. 6.22 FRANCE MARKET ANALYSIS BY DATA SOURCE
23. 6.23 FRANCE MARKET ANALYSIS BY TYPE OF INFECTION
24. 6.24 RUSSIA MARKET ANALYSIS BY DEPLOYMENT
25. 6.25 RUSSIA MARKET ANALYSIS BY APPLICATION
26. 6.26 RUSSIA MARKET ANALYSIS BY DATA SOURCE
27. 6.27 RUSSIA MARKET ANALYSIS BY TYPE OF INFECTION
28. 6.28 ITALY MARKET ANALYSIS BY DEPLOYMENT
29. 6.29 ITALY MARKET ANALYSIS BY APPLICATION
30. 6.30 ITALY MARKET ANALYSIS BY DATA SOURCE
31. 6.31 ITALY MARKET ANALYSIS BY TYPE OF INFECTION
32. 6.32 SPAIN MARKET ANALYSIS BY DEPLOYMENT
33. 6.33 SPAIN MARKET ANALYSIS BY APPLICATION
34. 6.34 SPAIN MARKET ANALYSIS BY DATA SOURCE
35. 6.35 SPAIN MARKET ANALYSIS BY TYPE OF INFECTION
36. 6.36 REST OF EUROPE MARKET ANALYSIS BY DEPLOYMENT
37. 6.37 REST OF EUROPE MARKET ANALYSIS BY APPLICATION
38. 6.38 REST OF EUROPE MARKET ANALYSIS BY DATA SOURCE
39. 6.39 REST OF EUROPE MARKET ANALYSIS BY TYPE OF INFECTION
40. 6.40 APAC MARKET ANALYSIS
41. 6.41 CHINA MARKET ANALYSIS BY DEPLOYMENT
42. 6.42 CHINA MARKET ANALYSIS BY APPLICATION
43. 6.43 CHINA MARKET ANALYSIS BY DATA SOURCE
44. 6.44 CHINA MARKET ANALYSIS BY TYPE OF INFECTION
45. 6.45 INDIA MARKET ANALYSIS BY DEPLOYMENT
46. 6.46 INDIA MARKET ANALYSIS BY APPLICATION
47. 6.47 INDIA MARKET ANALYSIS BY DATA SOURCE
48. 6.48 INDIA MARKET ANALYSIS BY TYPE OF INFECTION
49. 6.49 JAPAN MARKET ANALYSIS BY DEPLOYMENT
50. 6.50 JAPAN MARKET ANALYSIS BY APPLICATION
51. 6.51 JAPAN MARKET ANALYSIS BY DATA SOURCE
52. 6.52 JAPAN MARKET ANALYSIS BY TYPE OF INFECTION
53. 6.53 SOUTH KOREA MARKET ANALYSIS BY DEPLOYMENT
54. 6.54 SOUTH KOREA MARKET ANALYSIS BY APPLICATION
55. 6.55 SOUTH KOREA MARKET ANALYSIS BY DATA SOURCE
56. 6.56 SOUTH KOREA MARKET ANALYSIS BY TYPE OF INFECTION
57. 6.57 MALAYSIA MARKET ANALYSIS BY DEPLOYMENT
58. 6.58 MALAYSIA MARKET ANALYSIS BY APPLICATION
59. 6.59 MALAYSIA MARKET ANALYSIS BY DATA SOURCE
60. 6.60 MALAYSIA MARKET ANALYSIS BY TYPE OF INFECTION
61. 6.61 THAILAND MARKET ANALYSIS BY DEPLOYMENT
62. 6.62 THAILAND MARKET ANALYSIS BY APPLICATION
63. 6.63 THAILAND MARKET ANALYSIS BY DATA SOURCE
64. 6.64 THAILAND MARKET ANALYSIS BY TYPE OF INFECTION
65. 6.65 INDONESIA MARKET ANALYSIS BY DEPLOYMENT
66. 6.66 INDONESIA MARKET ANALYSIS BY APPLICATION
67. 6.67 INDONESIA MARKET ANALYSIS BY DATA SOURCE
68. 6.68 INDONESIA MARKET ANALYSIS BY TYPE OF INFECTION
69. 6.69 REST OF APAC MARKET ANALYSIS BY DEPLOYMENT
70. 6.70 REST OF APAC MARKET ANALYSIS BY APPLICATION
71. 6.71 REST OF APAC MARKET ANALYSIS BY DATA SOURCE
72. 6.72 REST OF APAC MARKET ANALYSIS BY TYPE OF INFECTION
73. 6.73 SOUTH AMERICA MARKET ANALYSIS
74. 6.74 BRAZIL MARKET ANALYSIS BY DEPLOYMENT
75. 6.75 BRAZIL MARKET ANALYSIS BY APPLICATION
76. 6.76 BRAZIL MARKET ANALYSIS BY DATA SOURCE
77. 6.77 BRAZIL MARKET ANALYSIS BY TYPE OF INFECTION
78. 6.78 MEXICO MARKET ANALYSIS BY DEPLOYMENT
79. 6.79 MEXICO MARKET ANALYSIS BY APPLICATION
80. 6.80 MEXICO MARKET ANALYSIS BY DATA SOURCE
81. 6.81 MEXICO MARKET ANALYSIS BY TYPE OF INFECTION
82. 6.82 ARGENTINA MARKET ANALYSIS BY DEPLOYMENT
83. 6.83 ARGENTINA MARKET ANALYSIS BY APPLICATION
84. 6.84 ARGENTINA MARKET ANALYSIS BY DATA SOURCE
85. 6.85 ARGENTINA MARKET ANALYSIS BY TYPE OF INFECTION
86. 6.86 REST OF SOUTH AMERICA MARKET ANALYSIS BY DEPLOYMENT
87. 6.87 REST OF SOUTH AMERICA MARKET ANALYSIS BY APPLICATION
88. 6.88 REST OF SOUTH AMERICA MARKET ANALYSIS BY DATA SOURCE
89. 6.89 REST OF SOUTH AMERICA MARKET ANALYSIS BY TYPE OF INFECTION
90. 6.90 MEA MARKET ANALYSIS
91. 6.91 GCC COUNTRIES MARKET ANALYSIS BY DEPLOYMENT
92. 6.92 GCC COUNTRIES MARKET ANALYSIS BY APPLICATION
93. 6.93 GCC COUNTRIES MARKET ANALYSIS BY DATA SOURCE
94. 6.94 GCC COUNTRIES MARKET ANALYSIS BY TYPE OF INFECTION
95. 6.95 SOUTH AFRICA MARKET ANALYSIS BY DEPLOYMENT
96. 6.96 SOUTH AFRICA MARKET ANALYSIS BY APPLICATION
97. 6.97 SOUTH AFRICA MARKET ANALYSIS BY DATA SOURCE
98. 6.98 SOUTH AFRICA MARKET ANALYSIS BY TYPE OF INFECTION
99. 6.99 REST OF MEA MARKET ANALYSIS BY DEPLOYMENT
100. 6.100 REST OF MEA MARKET ANALYSIS BY APPLICATION
101. 6.101 REST OF MEA MARKET ANALYSIS BY DATA SOURCE
102. 6.102 REST OF MEA MARKET ANALYSIS BY TYPE OF INFECTION
103. 6.103 KEY BUYING CRITERIA OF HEALTHCARE
104. 6.104 RESEARCH PROCESS OF MRFR
105. 6.105 DRO ANALYSIS OF HEALTHCARE
106. 6.106 DRIVERS IMPACT ANALYSIS: HEALTHCARE
107. 6.107 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE
108. 6.108 SUPPLY / VALUE CHAIN: HEALTHCARE
109. 6.109 HEALTHCARE, BY DEPLOYMENT, 2024 (% SHARE)
110. 6.110 HEALTHCARE, BY DEPLOYMENT, 2024 TO 2035 (USD Billion)
111. 6.111 HEALTHCARE, BY APPLICATION, 2024 (% SHARE)
112. 6.112 HEALTHCARE, BY APPLICATION, 2024 TO 2035 (USD Billion)
113. 6.113 HEALTHCARE, BY DATA SOURCE, 2024 (% SHARE)
114. 6.114 HEALTHCARE, BY DATA SOURCE, 2024 TO 2035 (USD Billion)
115. 6.115 HEALTHCARE, BY TYPE OF INFECTION, 2024 (% SHARE)
116. 6.116 HEALTHCARE, BY TYPE OF INFECTION, 2024 TO 2035 (USD Billion)
117. 6.117 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 North America MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY DEPLOYMENT, 2025-2035 (USD Billion)
  2. 7.2.2 BY APPLICATION, 2025-2035 (USD Billion)
  3. 7.2.3 BY DATA SOURCE, 2025-2035 (USD Billion)
  4. 7.2.4 BY TYPE OF INFECTION, 2025-2035 (USD Billion)
2. 7.3 US MARKET SIZE ESTIMATES; FORECAST
  1. 7.3.1 BY DEPLOYMENT, 2025-2035 (USD Billion)
  2. 7.3.2 BY APPLICATION, 2025-2035 (USD Billion)
  3. 7.3.3 BY DATA SOURCE, 2025-2035 (USD Billion)
  4. 7.3.4 BY TYPE OF INFECTION, 2025-2035 (USD Billion)
3. 7.4 Canada MARKET SIZE ESTIMATES; FORECAST
  1. 7.4.1 BY DEPLOYMENT, 2025-2035 (USD Billion)
  2. 7.4.2 BY APPLICATION, 2025-2035 (USD Billion)
  3. 7.4.3 BY DATA SOURCE, 2025-2035 (USD Billion)
  4. 7.4.4 BY TYPE OF INFECTION, 2025-2035 (USD Billion)
4. 7.5 Europe MARKET SIZE ESTIMATES; FORECAST
  1. 7.5.1 BY DEPLOYMENT, 2025-2035 (USD Billion)
  2. 7.5.2 BY APPLICATION, 2025-2035 (USD Billion)
  3. 7.5.3 BY DATA SOURCE, 2025-2035 (USD Billion)
  4. 7.5.4 BY TYPE OF INFECTION, 2025-2035 (USD Billion)
5. 7.6 Germany MARKET SIZE ESTIMATES; FORECAST
  1. 7.6.1 BY DEPLOYMENT, 2025-2035 (USD Billion)
  2. 7.6.2 BY APPLICATION, 2025-2035 (USD Billion)
  3. 7.6.3 BY DATA SOURCE, 2025-2035 (USD Billion)
  4. 7.6.4 BY TYPE OF INFECTION, 2025-2035 (USD Billion)
6. 7.7 UK MARKET SIZE ESTIMATES; FORECAST
  1. 7.7.1 BY DEPLOYMENT, 2025-2035 (USD Billion)
  2. 7.7.2 BY APPLICATION, 2025-2035 (USD Billion)
  3. 7.7.3 BY DATA SOURCE, 2025-2035 (USD Billion)
  4. 7.7.4 BY TYPE OF INFECTION, 2025-2035 (USD Billion)
7. 7.8 France MARKET SIZE ESTIMATES; FORECAST
  1. 7.8.1 BY DEPLOYMENT, 2025-2035 (USD Billion)
  2. 7.8.2 BY APPLICATION, 2025-2035 (USD Billion)
  3. 7.8.3 BY DATA SOURCE, 2025-2035 (USD Billion)
  4. 7.8.4 BY TYPE OF INFECTION, 2025-2035 (USD Billion)
8. 7.9 Russia MARKET SIZE ESTIMATES; FORECAST
  1. 7.9.1 BY DEPLOYMENT, 2025-2035 (USD Billion)
  2. 7.9.2 BY APPLICATION, 2025-2035 (USD Billion)
  3. 7.9.3 BY DATA SOURCE, 2025-2035 (USD Billion)
  4. 7.9.4 BY TYPE OF INFECTION, 2025-2035 (USD Billion)
9. 7.10 Italy MARKET SIZE ESTIMATES; FORECAST
  1. 7.10.1 BY DEPLOYMENT, 2025-2035 (USD Billion)
  2. 7.10.2 BY APPLICATION, 2025-2035 (USD Billion)
  3. 7.10.3 BY DATA SOURCE, 2025-2035 (USD Billion)
  4. 7.10.4 BY TYPE OF INFECTION, 2025-2035 (USD Billion)
10. 7.11 Spain MARKET SIZE ESTIMATES; FORECAST
  1. 7.11.1 BY DEPLOYMENT, 2025-2035 (USD Billion)
  2. 7.11.2 BY APPLICATION, 2025-2035 (USD Billion)
  3. 7.11.3 BY DATA SOURCE, 2025-2035 (USD Billion)
  4. 7.11.4 BY TYPE OF INFECTION, 2025-2035 (USD Billion)
11. 7.12 Rest of Europe MARKET SIZE ESTIMATES; FORECAST
  1. 7.12.1 BY DEPLOYMENT, 2025-2035 (USD Billion)
  2. 7.12.2 BY APPLICATION, 2025-2035 (USD Billion)
  3. 7.12.3 BY DATA SOURCE, 2025-2035 (USD Billion)
  4. 7.12.4 BY TYPE OF INFECTION, 2025-2035 (USD Billion)
12. 7.13 APAC MARKET SIZE ESTIMATES; FORECAST
  1. 7.13.1 BY DEPLOYMENT, 2025-2035 (USD Billion)
  2. 7.13.2 BY APPLICATION, 2025-2035 (USD Billion)
  3. 7.13.3 BY DATA SOURCE, 2025-2035 (USD Billion)
  4. 7.13.4 BY TYPE OF INFECTION, 2025-2035 (USD Billion)
13. 7.14 China MARKET SIZE ESTIMATES; FORECAST
  1. 7.14.1 BY DEPLOYMENT, 2025-2035 (USD Billion)
  2. 7.14.2 BY APPLICATION, 2025-2035 (USD Billion)
  3. 7.14.3 BY DATA SOURCE, 2025-2035 (USD Billion)
  4. 7.14.4 BY TYPE OF INFECTION, 2025-2035 (USD Billion)
14. 7.15 India MARKET SIZE ESTIMATES; FORECAST
  1. 7.15.1 BY DEPLOYMENT, 2025-2035 (USD Billion)
  2. 7.15.2 BY APPLICATION, 2025-2035 (USD Billion)
  3. 7.15.3 BY DATA SOURCE, 2025-2035 (USD Billion)
  4. 7.15.4 BY TYPE OF INFECTION, 2025-2035 (USD Billion)
15. 7.16 Japan MARKET SIZE ESTIMATES; FORECAST
  1. 7.16.1 BY DEPLOYMENT, 2025-2035 (USD Billion)
  2. 7.16.2 BY APPLICATION, 2025-2035 (USD Billion)
  3. 7.16.3 BY DATA SOURCE, 2025-2035 (USD Billion)
  4. 7.16.4 BY TYPE OF INFECTION, 2025-2035 (USD Billion)
16. 7.17 South Korea MARKET SIZE ESTIMATES; FORECAST
  1. 7.17.1 BY DEPLOYMENT, 2025-2035 (USD Billion)
  2. 7.17.2 BY APPLICATION, 2025-2035 (USD Billion)
  3. 7.17.3 BY DATA SOURCE, 2025-2035 (USD Billion)
  4. 7.17.4 BY TYPE OF INFECTION, 2025-2035 (USD Billion)
17. 7.18 Malaysia MARKET SIZE ESTIMATES; FORECAST
  1. 7.18.1 BY DEPLOYMENT, 2025-2035 (USD Billion)
  2. 7.18.2 BY APPLICATION, 2025-2035 (USD Billion)
  3. 7.18.3 BY DATA SOURCE, 2025-2035 (USD Billion)
  4. 7.18.4 BY TYPE OF INFECTION, 2025-2035 (USD Billion)
18. 7.19 Thailand MARKET SIZE ESTIMATES; FORECAST
  1. 7.19.1 BY DEPLOYMENT, 2025-2035 (USD Billion)
  2. 7.19.2 BY APPLICATION, 2025-2035 (USD Billion)
  3. 7.19.3 BY DATA SOURCE, 2025-2035 (USD Billion)
  4. 7.19.4 BY TYPE OF INFECTION, 2025-2035 (USD Billion)
19. 7.20 Indonesia MARKET SIZE ESTIMATES; FORECAST
  1. 7.20.1 BY DEPLOYMENT, 2025-2035 (USD Billion)
  2. 7.20.2 BY APPLICATION, 2025-2035 (USD Billion)
  3. 7.20.3 BY DATA SOURCE, 2025-2035 (USD Billion)
  4. 7.20.4 BY TYPE OF INFECTION, 2025-2035 (USD Billion)
20. 7.21 Rest of APAC MARKET SIZE ESTIMATES; FORECAST
  1. 7.21.1 BY DEPLOYMENT, 2025-2035 (USD Billion)
  2. 7.21.2 BY APPLICATION, 2025-2035 (USD Billion)
  3. 7.21.3 BY DATA SOURCE, 2025-2035 (USD Billion)
  4. 7.21.4 BY TYPE OF INFECTION, 2025-2035 (USD Billion)
21. 7.22 South America MARKET SIZE ESTIMATES; FORECAST
  1. 7.22.1 BY DEPLOYMENT, 2025-2035 (USD Billion)
  2. 7.22.2 BY APPLICATION, 2025-2035 (USD Billion)
  3. 7.22.3 BY DATA SOURCE, 2025-2035 (USD Billion)
  4. 7.22.4 BY TYPE OF INFECTION, 2025-2035 (USD Billion)
22. 7.23 Brazil MARKET SIZE ESTIMATES; FORECAST
  1. 7.23.1 BY DEPLOYMENT, 2025-2035 (USD Billion)
  2. 7.23.2 BY APPLICATION, 2025-2035 (USD Billion)
  3. 7.23.3 BY DATA SOURCE, 2025-2035 (USD Billion)
  4. 7.23.4 BY TYPE OF INFECTION, 2025-2035 (USD Billion)
23. 7.24 Mexico MARKET SIZE ESTIMATES; FORECAST
  1. 7.24.1 BY DEPLOYMENT, 2025-2035 (USD Billion)
  2. 7.24.2 BY APPLICATION, 2025-2035 (USD Billion)
  3. 7.24.3 BY DATA SOURCE, 2025-2035 (USD Billion)
  4. 7.24.4 BY TYPE OF INFECTION, 2025-2035 (USD Billion)
24. 7.25 Argentina MARKET SIZE ESTIMATES; FORECAST
  1. 7.25.1 BY DEPLOYMENT, 2025-2035 (USD Billion)
  2. 7.25.2 BY APPLICATION, 2025-2035 (USD Billion)
  3. 7.25.3 BY DATA SOURCE, 2025-2035 (USD Billion)
  4. 7.25.4 BY TYPE OF INFECTION, 2025-2035 (USD Billion)
25. 7.26 Rest of South America MARKET SIZE ESTIMATES; FORECAST
  1. 7.26.1 BY DEPLOYMENT, 2025-2035 (USD Billion)
  2. 7.26.2 BY APPLICATION, 2025-2035 (USD Billion)
  3. 7.26.3 BY DATA SOURCE, 2025-2035 (USD Billion)
  4. 7.26.4 BY TYPE OF INFECTION, 2025-2035 (USD Billion)
26. 7.27 MEA MARKET SIZE ESTIMATES; FORECAST
  1. 7.27.1 BY DEPLOYMENT, 2025-2035 (USD Billion)
  2. 7.27.2 BY APPLICATION, 2025-2035 (USD Billion)
  3. 7.27.3 BY DATA SOURCE, 2025-2035 (USD Billion)
  4. 7.27.4 BY TYPE OF INFECTION, 2025-2035 (USD Billion)
27. 7.28 GCC Countries MARKET SIZE ESTIMATES; FORECAST
  1. 7.28.1 BY DEPLOYMENT, 2025-2035 (USD Billion)
  2. 7.28.2 BY APPLICATION, 2025-2035 (USD Billion)
  3. 7.28.3 BY DATA SOURCE, 2025-2035 (USD Billion)
  4. 7.28.4 BY TYPE OF INFECTION, 2025-2035 (USD Billion)
28. 7.29 South Africa MARKET SIZE ESTIMATES; FORECAST
  1. 7.29.1 BY DEPLOYMENT, 2025-2035 (USD Billion)
  2. 7.29.2 BY APPLICATION, 2025-2035 (USD Billion)
  3. 7.29.3 BY DATA SOURCE, 2025-2035 (USD Billion)
  4. 7.29.4 BY TYPE OF INFECTION, 2025-2035 (USD Billion)
29. 7.30 Rest of MEA MARKET SIZE ESTIMATES; FORECAST
  1. 7.30.1 BY DEPLOYMENT, 2025-2035 (USD Billion)
  2. 7.30.2 BY APPLICATION, 2025-2035 (USD Billion)
  3. 7.30.3 BY DATA SOURCE, 2025-2035 (USD Billion)
  4. 7.30.4 BY TYPE OF INFECTION, 2025-2035 (USD Billion)
30. 7.31 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.31.1
1. 7.32 ACQUISITION/PARTNERSHIP
7.32.1

Certified Researchers

Customize Report

Healthcare Market Segmentation

Healthcare By Deployment (USD Billion, 2025-2035)

Cloud-based
On-premises

Healthcare By Application (USD Billion, 2025-2035)

Healthcare-associated infections (HAIs)
Antimicrobial resistance surveillance
Vaccine effectiveness monitoring

Healthcare By Data Source (USD Billion, 2025-2035)

Electronic health records (EHRs)
Laboratory information systems (LISs)
Patient portals

Healthcare By Type of Infection (USD Billion, 2025-2035)

Bacterial infections
Viral infections
Fungal infections

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”

Rob Kooiker Group Product Manager HVAC & Fire Protection GMA

“We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.”

Akif Moroglu Strategy & Business Development Director

Case Study

Aerospace & Defense

Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035

Features	License Type
Features	Single User	Multiuser License	Enterprise User
Price	$4,950	$5,950	$7,250
Maximum User Access Limit	1 User	Upto 10 Users	Unrestricted Access Throughout the Organization
Free Customization	✓	✓	✓
Direct Access to Analyst	✓	✓	✓
Deliverable Format	✓	✓	✓
Platform Access	✗	✗	✓
Discount on Next Purchase	10%	15%	15%
Printable Versions	✗	✗	✓